Page 140 - Ebook-Book JCMS 2025

A Comparison of Clinical Outcome Among Undenatured
Collagen type II, Glucosamine Sulfate and Diacerein on
Osteoarthritic Knee Treatment: A Double-blinded Randomized
Controlled Trial
Kit Awirotananon1, Keerati Chareancholvanich1, Rapeepat Narkbunnam1, Swist Chatmaitri2, Nath Adulkasem1
,
Paphon Hirunyachoke3, Chaturong Pornrattanamaneewong1*
1 Department of Orthopaedic Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University
2 Department of Orthopaedic Surgery, Ratchaphiphat Hospital
3 Department of Orthopaedic Surgery, Nakhonpathom Hospital
*Corresponding Author E-mail: toonchaturong@gmail.com
Background: Abstract
Osteoarthritis (OA) of the knee is commonly managed with various oral supplements.
However, their efficacy remains uncertain. This study aims to compare the efficacy of
supplement treatments, including glucosamine sulfate, diacerein, undenatured collagen
type II (UC-II), and placebo, in improving functional and radiographic outcomes.
Methods: A four-group, randomized, double-blind, placebo-controlled study evaluated 216 subjects
with mild to moderate knee OA. Patients were randomly allocated to receive either placebo,
glucosamine sulfate, diacerein, or UC-II for 24 weeks. We collected baseline demographic
data, physical performance metrics, and Western Ontario and McMaster Universities
Arthritis Index (WOMAC) scores. Our primary outcome measure was change in WOMAC
score. Secondary assessments included Numerical Pain Rating Scale (NPRS) scores,
rescue medication consumption, joint space width (JSW) measurements, and adverse
events. These parameters were evaluated at 12 and 24 weeks after intervention initiation.
Additionally, physical function was assessed using the 6-minute walk test and timed
up-and-go test at week 24. To investigate potential carry-over effects, all measurements
were repeated at week 36.
Results: All treatment groups demonstrated trends toward improvement in WOMAC score, NPRS,
and performance tests when compared to baseline. However, no significant differences
were found among the four treatment groups in both primary and secondary outcomes
at 12, 24, and 36 weeks. There were no differences in rescue medication use, and adverse
events were minimal across all groups.
Conclusion: The administration of glucosamine sulfate, diacerein, and UC-II did not significantly
improve the WOMAC score at 12, 24, and 36 weeks when compared to placebo in mild to
moderate knee OA.
138 Joint Conference in Medical Sciences 2025